Beurs gesloten -
Bombay S.E.
12:00:48 30-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
4.916
INR
|
+2,97%
|
|
+4,59%
|
-0,60%
|
Fiscaal tijdperk: Juni |
2018
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
39.336
|
67.513
|
92.857
|
69.507
|
87.133
|
Bedrijfswaarde
1 |
26.901
|
61.122
|
88.293
|
66.341
|
82.903
|
K/w-verhouding
|
4,69
x
|
40,7
x
|
52,5
x
|
36,1
x
|
38
x
|
Dividendrendement
|
1,01%
|
0,69%
|
0,72%
|
1,25%
|
1,81%
|
Marktkapitalisatie/omzet
|
4,63
x
|
7,6
x
|
9,21
x
|
6,24
x
|
7,09
x
|
Bedrijfswaarde/omzet
|
3,17
x
|
6,88
x
|
8,75
x
|
5,95
x
|
6,74
x
|
Bedrijfswaarde/EBITDA
|
17,7
x
|
29,3
x
|
36,2
x
|
25,1
x
|
26
x
|
Bedrijfswaarde/FCF
|
16,6
x
|
-
|
49,3
x
|
56,6
x
|
48,3
x
|
FCF Yield
|
6,01%
|
-
|
2,03%
|
1,77%
|
2,07%
|
Price to Book
|
2,55
x
|
7,45
x
|
13,2
x
|
11,3
x
|
11,6
x
|
Aantal aandelen (in duizenden)
|
16.599
|
16.599
|
16.599
|
16.599
|
16.599
|
Referentieprijs
2 |
2.370
|
4.067
|
5.594
|
4.187
|
5.249
|
Datum van publicatie
|
8/05/19
|
3/11/20
|
17/10/21
|
31/10/22
|
23/08/23
|
Fiscaal tijdperk: Juni |
2018
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
8.490
|
8.886
|
10.087
|
11.144
|
12.296
|
EBITDA
1 |
1.517
|
2.088
|
2.441
|
2.648
|
3.188
|
Bedrijfsresultaat (EBIT)
1 |
1.270
|
1.892
|
2.188
|
2.426
|
2.958
|
Operationele Marge
|
14,96%
|
21,29%
|
21,69%
|
21,77%
|
24,06%
|
Resultaat voor belastingen (EBT)
1 |
1.580
|
2.199
|
2.333
|
2.534
|
3.142
|
Nettowinst (verlies)
1 |
8.387
|
1.659
|
1.768
|
1.925
|
2.295
|
Nettomarge
|
98,79%
|
18,67%
|
17,53%
|
17,28%
|
18,66%
|
WPA
2 |
505,3
|
99,87
|
106,5
|
116,0
|
138,0
|
Free Cash Flow
1 |
1.617
|
-
|
1.789
|
1.172
|
1.716
|
FCF-marge
|
19,05%
|
-
|
17,74%
|
10,51%
|
13,95%
|
Kasstroomconversie (ebitda)
|
106,58%
|
-
|
73,31%
|
44,25%
|
53,83%
|
Kasstroomconversie (nettowinst)
|
19,28%
|
-
|
101,2%
|
60,86%
|
74,77%
|
Dividend per aandeel
2 |
24,00
|
28,00
|
40,00
|
52,50
|
95,00
|
Datum van publicatie
|
8/05/19
|
3/11/20
|
17/10/21
|
31/10/22
|
23/08/23
|
Fiscaal tijdperk: Juni |
2018
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
12.434
|
6.391
|
4.564
|
3.166
|
4.231
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1.617
|
-
|
1.789
|
1.172
|
1.716
|
ROE (netto-inkomsten/eigen vermogen)
|
8,95%
|
-
|
22%
|
29,2%
|
33,6%
|
ROA (netto-inkomsten/totale activa)
|
5,77%
|
-
|
12,7%
|
16,1%
|
18,6%
|
Totale activa
1 |
145.293
|
-
|
13.973
|
11.937
|
12.344
|
Nettoactief per aandeel
2 |
928,0
|
546,0
|
424,0
|
371,0
|
452,0
|
Cashflow per aandeel
2 |
749,0
|
385,0
|
280,0
|
192,0
|
262,0
|
Capex
1 |
267
|
155
|
526
|
379
|
425
|
Capex/omzet
|
3,15%
|
1,75%
|
5,21%
|
3,4%
|
3,45%
|
Datum van publicatie
|
8/05/19
|
3/11/20
|
17/10/21
|
31/10/22
|
23/08/23
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -0,60% | 978 mln. | | +19,27% | 43,18 mld. | | +24,05% | 23,23 mld. | | +15,11% | 14,6 mld. | | +38,36% | 11,5 mld. | | -7,63% | 6,79 mld. | | -0,05% | 6,79 mld. | | -8,87% | 5,73 mld. | | +10,21% | 5,31 mld. | | -2,27% | 4,81 mld. |
Generieke geneesmiddelen
|